| 28/08/25 | 15:00:00 | 28 Aug 2025 | | Holding(s) in Company |
| 26/08/25 | 15:00:00 | 26 Aug 2025 | | Holding(s) in Company |
| 21/08/25 | 15:00:00 | 21 Aug 2025 | | Holding(s) in Company |
| 18/08/25 | 15:00:00 | 18 Aug 2025 | | Director/PDMR Shareholding |
| 15/08/25 | 15:00:01 | 15 Aug 2025 | | Holding(s) in Company |
| 12/08/25 | 15:00:00 | 12 Aug 2025 | | Holding(s) in Company |
| 29/07/25 | 07:00:12 | 29 Jul 2025 | | H1 and Q2 2025 results |
| 24/07/25 | 07:00:10 | 24 Jul 2025 | | Gefurulimab nanobody met Phase III endpoints |
| 22/07/25 | 07:00:07 | 22 Jul 2025 | | AstraZeneca plans to invest $50bn in the US |
| 16/07/25 | 07:00:07 | 16 Jul 2025 | | Update on anselamimab in AL amyloidosis |
| 14/07/25 | 07:00:11 | 14 Jul 2025 | | Baxdrostat met primary endpt in BaxHTN PhIII trial |
| 04/07/25 | 07:00:06 | 4 Jul 2025 | | Imfinzi approved in the EU for bladder cancer |
| 24/06/25 | 07:00:08 | 24 Jun 2025 | | Datroway approved in US for EGFRm lung cancer |
| 17/06/25 | 11:45:00 | 17 Jun 2025 | | Holding(s) in Company |
| 13/06/25 | 09:30:00 | 13 Jun 2025 | | AstraZeneca enters into collaboration with CSPC |
| 12/06/25 | 15:00:01 | 12 Jun 2025 | | Director/PDMR Shareholding |
| 06/06/25 | 07:00:10 | 6 Jun 2025 | | Fixed-duration Calquence approved in EU for 1L CLL |
| 27/05/25 | 07:00:07 | 27 May 2025 | | Imfinzi recommended in EU for bladder cancer |
| 23/05/25 | 10:00:00 | 23 May 2025 | | Director/PDMR Shareholding |
| 21/05/25 | 13:45:00 | 21 May 2025 | | Director Declaration |
| 20/05/25 | 07:00:09 | 20 May 2025 | | Acquisition of EsoBiotec completed |
| 09/05/25 | 07:00:05 | 9 May 2025 | | Imfinzi improved DFS in early bladder cancer |
| 07/05/25 | 07:30:00 | 7 May 2025 | | Enhertu improved pCR in early-stage breast cancer |
| 06/05/25 | 07:00:14 | 6 May 2025 | | Calquence combination approved in EU for 1L MCL |
| 02/05/25 | 07:00:03 | 2 May 2025 | | Breztri met primary endpoints in Ph3 asthma trials |
| 01/05/25 | 16:00:00 | 1 May 2025 | | Director/PDMR Shareholding |
| 29/04/25 | 07:10:02 | 29 Apr 2025 | | Fixed-duration Calquence recommended in EU for CLL |
| 29/04/25 | 07:05:01 | 29 Apr 2025 | | Update on CAPItello-280 Phase III trial |
| 29/04/25 | 07:00:09 | 29 Apr 2025 | | 1st Quarter Results |
| 22/04/25 | 07:00:13 | 22 Apr 2025 | | Enhertu combination improved PFS in 1L HER2+ mBC |
| 11/04/25 | 17:30:00 | 11 Apr 2025 | | Result of AGM |
| 04/04/25 | 07:05:00 | 4 Apr 2025 | | Imfinzi approved in EU for AEGEAN |
| 04/04/25 | 07:00:01 | 4 Apr 2025 | | Enhertu approved in EU in post-ET breast cancer |
| 31/03/25 | 07:05:00 | 31 Mar 2025 | | Calquence recommended for EU approval in 1L MCL |
| 31/03/25 | 07:00:11 | 31 Mar 2025 | | Imfinzi approved in the US for bladder cancer |
| 21/03/25 | 10:58:49 | 21 Mar 2025 | | AZN invests $2.5bn in Beijing R&D & manufacturing |
| 17/03/25 | 07:10:01 | 17 Mar 2025 | | Eneboparatide Phase III trial met primary endpoint |
| 17/03/25 | 07:05:00 | 17 Mar 2025 | | Imfinzi approved in EU for limited-stage SCLC |
| 17/03/25 | 07:00:09 | 17 Mar 2025 | | AstraZeneca to acquire EsoBiotec |
| 12/03/25 | 18:00:00 | 12 Mar 2025 | | Holding(s) in Company |
| 07/03/25 | 15:00:00 | 7 Mar 2025 | | Director/PDMR Shareholding |
| 07/03/25 | 11:00:01 | 7 Mar 2025 | | Notice of AGM |
| 07/03/25 | 07:00:09 | 7 Mar 2025 | | Imfinzi improved EFS in early-stage gastric cancer |
| 06/03/25 | 15:00:01 | 6 Mar 2025 | | Director/PDMR Shareholding |
| 05/03/25 | 15:00:01 | 5 Mar 2025 | | Director/PDMR Shareholding |
| 03/03/25 | 07:00:04 | 3 Mar 2025 | | Imfinzi recommended for EU approval for AEGEAN |
| 28/02/25 | 13:00:00 | 28 Feb 2025 | | Enhertu recommended in EU in post-ET breast cancer |
| 26/02/25 | 07:00:05 | 26 Feb 2025 | | Camizestrant improved PFS in 1L HR+ breast cancer |
| 19/02/25 | 07:00:06 | 19 Feb 2025 | | Filing of Form 20-F with SEC |
| 18/02/25 | 14:00:00 | 18 Feb 2025 | | Holding(s) in Company |
